Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Personalized neoantigen vaccines have shown strong immunogenicity in clinical trial, but still face various challenges in facilitating an efficient antitumor immune response. Here, a personalized neoantigen nanovaccine (PNVAC) platform for adjuvant cancer immunotherapy is generated. PNVAC triggers superior protective efficacy against tumor recurrence and promotes longer survival than free neoantigens, especially when combined with anti-PD-1 treatment in a murine tumor model. A phase I clinical trial (ChiCTR1800017319) is initiated to evaluate the safety, immunogenicity, and prophylactic effect of PNVAC on preventing tumor recurrence in patients with high-risk gastric/gastroesophageal junction cancer after adjuvant chemotherapy of postsurgical resection. The one- and two-year disease-free survival rates are significantly higher than historical record. PNVAC induces both CD4 and CD8 T cell responses as well as antigen-experienced memory T cell phenotype. Furthermore, the immune response is persistent and remains evident one year after the vaccination. This work provides a safe and feasible strategy for developing neoantigen vaccines to delay gastric cancer recurrence after surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811442 | PMC |
| http://dx.doi.org/10.1002/advs.202203298 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new frontier in oncology: Understanding the landscape of cancer vaccines.
J Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDFA phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.
Front Immunol
September 2025
Department of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Background: Neoantigen-based vaccines show promising therapeutic potential in solid tumors such as melanoma, GBM, NSCLC, and CRC. However, clinical responses remain suboptimal in stage IV patients, due to ineffective T-cell function and high tumor burdens. To overcome these limitations, our study investigates a combination strategy using neoantigen peptide vaccines and precision critical lesion radiotherapy (CLERT), which delivers immunomodulatory doses to key tumor regions synergistically enhance immune activation and inhibit progression in multifocal stage IV patients.
View Article and Find Full Text PDFEmerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery.
Nanomedicine (Lond)
September 2025
Key Laboratory of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, China.
Lipid nanoparticles (LNPs) enable RNA delivery, primarily via intramuscular (IM) injection, catalyzing breakthroughs like the Pfizer-BioNTech and Moderna COVID-19 vaccines. LNPs encapsulate RNA, using ionizable lipids for endosomal escape and PEG-lipids for stability. IM administration leverages muscle tissue's immune-rich environment, enabling localized antigen production, reduced systemic toxicity, and scalability.
View Article and Find Full Text PDFThe role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.
J Hematol Oncol
September 2025
Department of General Surgery, State Key Lab of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Cancer immunotherapy has revolutionized oncology by leveraging the immune system to combat tumors. Among various biomarkers, neoantigens and tumor mutational burden (TMB) have emerged as critical factors in tailoring personalized treatments. Neoantigens are tumor-specific peptides displayed on cancer cell surfaces, derived from somatic mutations.
View Article and Find Full Text PDFSpleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model.
J Nanobiotechnology
September 2025
Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Personalized neoantigen peptide vaccines have shown remarkable anti-tumor activity across diverse cancer types. With the rapid advancement of messenger RNA (mRNA) delivery technologies during the coronavirus disease of 2019 (COVID-19) pandemic, mRNA-based cancer vaccines have emerged as a promising therapeutic approach because of their scalable production, safety, and capacity to elicit potent immune responses. However, the predominant distribution of mRNA delivery systems in the liver may lead to hepatic damage and restrict therapeutic accessibility.
View Article and Find Full Text PDF